ARTICLE | Product Development
CRISPR Therapeutics advances CAR T modality in T cell cancers
CRISPR-edited CAR T CTX130 generates responses in challenging T cell lymphoma indications
May 12, 2022 11:04 PM UTC
The first clinical data from CRISPR Therapeutics’ CD70-targeted CAR T cell therapy demonstrate the potential for gene editing to drive allogeneic CAR T cell efficacy and move the cells into historically challenging indications.
Though several CAR T cells for T cell cancers have progressed to the clinic, CRISPR Therapeutics AG (NASDAQ:CRSP) and another company set to present at the European Hematology Association (EHA) conference are the first to report positive clinical efficacy data. CRISPR Therapeutics’s data stand out for their high response rates...